Denver News Updates

Vasomotor Symptoms Overview

Vasomotor symptoms (VMS) or hot flashes and night sweats, are hallmarks of the menopausal transition (MT) and can significantly affect quality of life. Up to 80% of women experience VMS during menopause 5,6 and a majority of women rate them as moderate-to-severe.

“Vasomotor Symptoms Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vasomotor Symptoms Market.

The Vasomotor Symptoms Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Vasomotor Symptoms Pipeline Report:

• Companies across the globe are diligently working toward developing novel Vasomotor Symptoms treatment therapies with a considerable amount of success over the years. Vasomotor Symptoms Key players such as – MenoGeniX, Inc., Acer Therapeutics, Fervent Pharmaceuticals, Mitsubishi Tanabe Pharma, Bayer, Mithra Pharmaceuticals, and others, are developing therapies for the Vasomotor Symptoms treatment 
• Vasomotor Symptoms Emerging therapies such as – MNGX-100, ACER-801, FP-101, MT-8554, Elinzanetant, Estetrol, and others are expected to have a significant impact on the Vasomotor Symptoms market in the coming years.   
• In October 2021, Bayer initiated a double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women. The participants in this study will take two capsules of either elinzanetant or the placebo once a day
• In August 2021, Bayer initiated a double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women

Route of Administration

Vasomotor Symptoms pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Vasomotor Symptoms Pipeline Therapeutics Assessment

• Vasomotor Symptoms Assessment by Product Type
• Vasomotor Symptoms By Stage and Product Type
• Vasomotor Symptoms Assessment by Route of Administration
• Vasomotor Symptoms By Stage and Route of Administration
• Vasomotor Symptoms Assessment by Molecule Type
• Vasomotor Symptoms by Stage and Molecule Type

DelveInsight’s Vasomotor Symptoms Report covers around 9+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Vasomotor Symptoms Therapeutics Market include:

Key companies developing therapies for Vasomotor Symptoms are – Zhejiang Huahai Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Hikma Pharmaceutical PLC, Amneal Pharmaceuticals LLC., Alembic Pharmaceuticals Ltd., Zydus Group, Dr. Reddy’s Laboratories Ltd., Abbvie, Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma, Endo Pharmaceuticals plc., Lupin, Novartis AG, WOCKHARDT, and others.

Emerging Vasomotor Symptoms Drugs Under Different Phases of Clinical Development Include:

• MNGX-100: MenoGeniX, Inc.
• ACER-801: Acer Therapeutics
• Donesta: Mithra Pharmaceuticals
• Q-122: QUE Oncology
• FP-101: Fervent Pharmaceuticals
• MT-8554: Mitsubishi Tanabe Pharma
• Elinzanetant: Bayer
• Estetrol: Mithra Pharmaceuticals

Get a Free Sample PDF Report to know more about Vasomotor Symptoms Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/vasomotor-symptoms-of-menopause-pipeline-insight

Vasomotor Symptoms Pipeline Analysis:

The Vasomotor Symptoms pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Vasomotor Symptoms with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vasomotor Symptoms Treatment.
• Vasomotor Symptoms key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Vasomotor Symptoms Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vasomotor Symptoms market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Vasomotor Symptoms product details are provided in the report. Download the Vasomotor Symptoms pipeline report to learn more about the emerging Vasomotor Symptoms therapies

Vasomotor Symptoms Pipeline Market Drivers

• Government initiatives focusing more on women’s health
• Development of advanced products with alternative mode of administration

Vasomotor Symptoms Pipeline Market Barriers

• Side effects of post consumption of medication
• Physiology underlying Vasomotor Symptoms is complex and not fully understood

Scope of Vasomotor Symptoms Pipeline Drug Insight    

• Coverage: Global
• Key Vasomotor Symptoms Companies: MenoGeniX, Inc., Acer Therapeutics, Fervent Pharmaceuticals, Mitsubishi Tanabe Pharma, Bayer, Mithra Pharmaceuticals, and others
• Key Vasomotor Symptoms Therapies: MNGX-100, ACER-801, FP-101, MT-8554, Elinzanetant, Estetrol, and others
• Vasomotor Symptoms Therapeutic Assessment: Vasomotor Symptoms current marketed and Vasomotor Symptoms emerging therapies
• Vasomotor Symptoms Market Dynamics: Vasomotor Symptoms market drivers and Vasomotor Symptoms market barriers 

Request for Sample PDF Report for Vasomotor Symptoms Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Vasomotor Symptoms drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis